Modified peptides and their applications in analgesia

By developing polypeptides targeting α7nAChR and α9nAChR, using non-natural amino acids and intramolecular disulfide bonds, existing analgesic drugs have been solved for poor efficacy and addictive neuropathic pain, achieving safe and efficient analgesic effects. .

CN118159550BActive Publication Date: 2024-11-01NANJING ANJI BIOLOGICAL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202480000220.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-06-21
Filing Date
2024-01-24
Publication Date
2024-11-01
Estimated Expiration
2044-01-24

AI Technical Summary

Technical Problem

Existing analgesic drugs are difficult to effectively target different types of neuropathic pain, and there are addictive and adverse reactions, especially drugs targeting α9α10 nicotinic acetylcholine receptors in the human body, resulting in limited clinical application.

Method used

A polypeptide targeting α7nAChR and α9nAChR is developed. By introducing non-natural amino acids and intramolecular disulfide bonds, the stability and analgesic efficacy of the peptide are improved, and the species difference is avoided. Simple synthesis technology and low-dose administration are adopted. Reduce production costs and patient burden.

Benefits of technology

It significantly improves the half-life of the peptide in the body and the duration of analgesics, reduces the risk of addiction, improves clinical drug compliance, and provides a safe and effective new non-opioid analgesics.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118159550B_ABST
    Figure CN118159550B_ABST
Patent Text Reader

Abstract

The present application relates to a peptide or a derivative thereof, a pharmaceutical composition comprising the peptide or a derivative thereof, and their use in treating pain.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to application PCT / CN2023 / 101880 filed on June 21, 2023. The prior application is deemed to be part of the disclosure of this application and is incorporated into this application in its entirety. Technical Field

[0003] The present application relates to the field of biomedicine, and specifically to a peptide or its derivatives and their use in analgesia. Background Art

[0004] Neuropathic pain refers to pain caused by lesions or diseases of the somatic sensory nervous system. It is a common chronic pain that seriously affects the quality of life of patients. According to statistics, about 8% of the world's population suffers from it (GILRON I, BARONR, JENSEN T. Neuropathic pain: principles of diagnosis and treatment [J]. Mayo Clin Proc, 2015, 90 (4): 532-545). Metabolic disorders (such as diabetic neuropathy), nerve entrapment, tumor-related pain, post-stroke pain, Parkinson's disease-related pain, post-spinal cord injury pain and trigeminal neuralgia, glossopharyngeal neuralgia, viral infections such as post-herpetic neuralgia, etc. are all typical neuropathic pain (SZOK D, TAJTI J, A, et al. Therapeutic approaches for peripheral and central neuropathic pain[J]. Behav Neurol, 2019, 2019: 8685954. and Jensen TS, Baron R, Haanp M, et al. A new definition of neuropathic pain[J]. Pain, 2011, 152(10): 2204 -2205).

[0005] Peripheral neuropathy is characterized by nerve damage and axonal loss and can be divided into inherited or acquired forms. Acquired peripheral neuropathy has been associated with a variety of causes, including exposure to toxic agents, among which pain induced by anti-tumor compounds is called chemotherapy-induced peripheral neuropathy (CIPN). A review summarizes the neuroimmune interactions in several preclinical studies of CIPN, indicating a link between chemotherapeutic agents and neurotoxicity. Studies have demonstrated the involvement of immune responses (innate and adaptive) as well as the stimulation and secretion of mediators (cytokines and chemokines) as possible causes of pain symptoms. In addition, neuroinflammatory components have also been shown in the spinal cord, with microglia and astrocytes playing an important role in CIPN (Front Immunol. 2021 Feb 4:11:626687).

[0006] Nicotinic acetylcholine receptor (nAChR) is a membrane protein with important physiological functions that is ubiquitous in nature. It can regulate a series of physiological functions of organisms, such as pain, cognition, memory, anxiety, etc. Acetylcholine receptors are widely present in nerve cells and are closely related to analgesia. Its subtypes are mainly α7, α9α10, etc. (see, for example, Hone AJ et al., Nicotinic acetylcholine receptors in neuropathic and inflammatory pain, FEBSlett. 2018 April; 592(7): 1045–1062 and Wu Pei et al., The role of α7 nicotinic acetylcholine receptor in regulating animal inflammatory response, Journal of Animal Nutrition, 2021, 33(11): 6001-6008). Cone snails are carnivorous molluscs and are the general term for Conus snails. There are about 700 species of cone snails in the world, mainly distributed in tropical waters. Conotoxin is a neurotoxin secreted by cone snails, mainly composed of 10 to 30 amino acids and containing disulfide bonds. The team of Professor Olivera at the University of Utah, USA, separated and identified the sequences and biological activities of various conotoxins, and found that conotoxins may become potential drugs for the treatment of various neurological diseases, which has triggered a wave of research on the development, structural modification and mechanism of action of conotoxins by researchers at home and abroad. Among them, Vc1.1, also known as ACV1, is a polypeptide containing 16 amino acids and two pairs of disulfide bonds. It is an α-conotoxin with analgesic effects isolated from Conus victoriae. Vc1.1 is a selective antagonist of α9α10 nicotinic acetylcholine receptors (nAChR) and has a therapeutic effect on neuropathic pain in rat sciatica (CCI) and neuropathic pain (PNL) models. However, due to the differences between α9α10nAChR in humans and mice, Vc1.1 had already entered the second phase of clinical trials. As a result, the activity of human α9α10nAChR decreased 100 times compared with mouse α9α10nAChR, forcing relevant institutions to suspend clinical research. Lorenzo Di Cesare Mannelli et al. studied the analgesic effect and mechanism of conotoxin peptide RgIA by ligating the rat sciatic nerve in a chronic constriction injury (CCI) model. Histological analysis of the sciatic nerve showed that RgIA could prevent CCI-induced reduction in axonal density and diameter, myelin loss and fiber reduction. In addition, RgIA significantly reduced edema and inflammatory infiltration, including a reduction in CD86+ macrophages. In the dorsal horn of the spinal cord, RgIA prevented CCI-induced activation of microglia and astrocytes.These data suggest that the peptide RgIA may represent a new class of therapeutic agents for neuropathic pain that can protect peripheral nerve tissue and prevent central maladaptive plasticity by inhibiting glial cell activation (PAIN:155(2014)1986–1995).

[0007] Ziconotide was approved by the FDA in 2004 for the treatment of severe chronic pain. It was originally isolated from the venom of Conus magus and contains 25 amino acids and three pairs of disulfide bonds. As a selective Cav2.2 channel antagonist, ziconotide blocks Ca 2+ Ziconotide can inhibit the release of excitatory neurotransmitters from afferent nerve endings, and its analgesic effect is 1000 times that of opioids. However, the special administration method of intrathecal injection and a series of adverse reactions of the central nervous system make patients' compliance poor, thus limiting the widespread application of ziconotide.

[0008] Therefore, there is an urgent need to develop an improved peptide that acts on nicotinic acetylcholine receptors and can effectively relieve pain and / or reduce adverse reactions. Summary of the invention

[0009] The targets targeted by the polypeptide of the present application include α7nAChR and α9nAChR, and the targeted targets are acetylcholine receptors of human sequences. This can avoid the reduced activity of conotoxin Vc1.1 due to species differences and similar risks. The polypeptide sequence of the present application introduces multiple non-natural amino acids and the polypeptide structure contains a pair of intramolecular disulfide bonds, which enhances the stability of the polypeptide, significantly increases the half-life of the polypeptide in the body, and significantly prolongs the duration of the analgesic effect. Pain is a very serious clinical problem that can have an adverse effect on the quality of life of patients and their families. However, existing analgesics cannot specifically solve different types of pain, and there are also adverse reactions to long-term medication, such as the addiction of opioids, and long-term use will cause adverse consequences of drug abuse. Polypeptides have inherent safety advantages. The polypeptide synthesis process of the present application is simple and easy to commercialize, and it is expected to be a new type of safe and effective analgesic.

[0010] From the results of animal experiments, the peptide of the present application has a faster onset time than the clinical analgesic drug pregabalin, and the stability of the peptide in the application has been significantly improved compared with the parent peptide AJ003 in human plasma. From the animal experimental data, it can also be found that the duration of the analgesic effect of the modified peptide is significantly extended compared with the parent peptide. The polypeptide of the present application belongs to a new type of non-opioid analgesic drug. Since its target is mainly present in peripheral nerve tissue, it will not cause toxic and side effects such as drug addiction in the later clinical stage. Compared with the only conotoxin peptide ziconotide currently on the market, the peptide of the present application does not need to adopt the complex administration method of intrathecal instillation, which is conducive to improving the medication compliance of clinical patients. In addition, ziconotide is composed of 25 amino acids, and the peptide sequence contains 3 pairs of disulfide bonds, the preparation process is complicated, and the production cost is greatly increased. The peptide of the present application is composed of 13 amino acids, contains only 1 pair of disulfide bonds, the production and preparation process is simple, the solid phase peptide synthesis technology is currently very mature, and its synthesis characteristics are very conducive to automated large-scale production, which can greatly reduce the cost of drug production and reduce the medical burden of patients. Furthermore, the peptide of the present application has a low administration dose and exhibits significant analgesic activity even at a low dose.

[0011] In a first aspect of the present disclosure, a peptide comprising any one sequence selected from SEQ ID NOs: 1-34 or a derivative thereof is provided.

[0012] In a second aspect of the present disclosure, provided is a peptide comprising any one sequence selected from SEQ ID NOs: 1-34 having conservative substitutions or a derivative thereof.

[0013] In a third aspect of the present disclosure, there is provided a peptide or a derivative thereof comprising the following formula I or formula I with conservative substitutions in order from N-terminus to C-terminus,

[0014] Gly-Ser-Cys-Ser-X1-X2-X3-X4-(D-Cys)-X5-X6-X7-X8 Formula I

[0015] The 3rd Cys and the 9th D-Cys in Formula I form a pair of intramolecular disulfide bonds, D-Cys represents D-cysteine, "-" between amino acid residues represents a peptide bond, the C-terminus of the peptide or its derivative is a free carboxyl group or an amide, and X1 is Thr or D-Thr, X5 is selected from any one of Ala, Val and D-Val, and X2-X4 and X6-X8 are independently any one of amino acids.

[0016] In one embodiment of the present disclosure, the 3rd Cys and the 9th D-Cys in the above formula I form a pair of intramolecular disulfide bonds, the C-terminus of the peptide or its derivative is a free carboxyl group or an amide, and X1 is Thr or D-Thr, X5 is selected from any one of Ala, Val and D-Val, X2 is selected from any one of Pro, D-Pro and Hyp, X3 is selected from any one of Pro, D-Pro and Hyp, X4 is selected from any one of Ser, D-Ser, Ala and Aib, X6 is selected from any one of Ala, Leu, D-Leu, Ile, ABu and Nle, X7 is selected from any one of Tyr, D-Tyr, Ala, Trp, Phe and Bip, and X8 is selected from any one of Ser, D-Ser, Ala, and Orn.

[0017] In one embodiment of the present disclosure, the above-mentioned Formula I with conservative substitutions has 1, 2, 3, 4 or 5 amino acid conservative substitutions. In one embodiment of the present disclosure, the above-mentioned Formula I with conservative substitutions has at least 65% sequence identity, at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity or at least 95% sequence identity with Formula I without conservative substitutions.

[0018] In a preferred embodiment of the present disclosure, the peptide or its derivative comprises any one sequence selected from the group consisting of SEQ ID NO: 1-5, SEQ ID NO: 10-16 and SEQ ID NO: 20-34, SEQ ID NO: 1-5, SEQ ID NO: 10-16 and SEQ ID NO: 20-34 with conservative substitutions. In a more preferred embodiment of the present disclosure, the peptide or its derivative comprises any one sequence selected from the group consisting of SEQ ID NO: 26, 28 and 32, SEQ ID NO: 26, 28 and 32 with conservative substitutions.

[0019] In one embodiment of the present disclosure, the above-mentioned sequences with conservative substitutions have 1, 2, 3, 4 or 5 amino acid conservative substitutions, respectively. In one embodiment of the present disclosure, the above-mentioned sequences with conservative substitutions have at least 65% sequence identity, at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity or at least 95% sequence identity with the sequences without conservative substitutions.

[0020] In the fourth aspect of the present disclosure, a polynucleotide is provided, which encodes the peptide or its derivative according to the present disclosure.

[0021] In a fifth aspect of the present disclosure, an expression vector is provided, which expresses the polynucleotide according to the present disclosure.

[0022] In a sixth aspect of the present disclosure, a host cell is provided, which comprises the polynucleotide according to the present disclosure or the expression vector according to the present disclosure.

[0023] In the seventh aspect of the present disclosure, a pharmaceutical composition is provided, comprising the peptide or its derivative according to the present disclosure and a pharmaceutically acceptable carrier or salt thereof. The present disclosure also provides a pharmaceutical composition, comprising the peptide or its derivative, polynucleotide, expression vector or host cell according to the present disclosure, and a pharmaceutically acceptable carrier or salt thereof.

[0024] In the eighth aspect of the present disclosure, the use of the peptide or its derivative according to the present disclosure or the pharmaceutical composition according to the present disclosure in the preparation of a drug for treating pain is provided. The present disclosure also provides the use of the peptide or its derivative according to the present disclosure, the polynucleotide according to the present disclosure, the expression vector according to the present disclosure, the host cell according to the present disclosure or the pharmaceutical composition according to the present disclosure in the preparation of a drug for treating pain.

[0025] In the ninth aspect of the present disclosure, a method for treating pain is provided, the method comprising administering a therapeutically effective amount of a peptide or a derivative thereof according to the present disclosure or a pharmaceutical composition according to the present disclosure to a subject in need thereof. The present disclosure also provides a method for treating pain, the method comprising administering a therapeutically effective amount of a peptide or a derivative thereof, a polynucleotide, an expression vector, a host cell or a pharmaceutical composition according to the present disclosure to a subject in need thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The following provides a brief description of the drawings, which are used to illustrate exemplary embodiments disclosed herein and not to limit these embodiments.

[0027] Figure 1 A line graph showing the change in the main peak area of ​​polypeptide AJ003-1 in Example 3 over time is shown.

[0028] Figure 2 A line graph showing the change in the main peak area of ​​polypeptide AJ003-34 in Example 3 over time.

[0029] Figure 3A line graph showing the change in the main peak area of ​​polypeptide AJ003-35 in Example 3 over time.

[0030] Figure 4 A line graph showing the change in the main peak area of ​​polypeptide AJ003-36 in Example 3 over time.

[0031] Figure 5 A line graph showing the change in the main peak area of ​​polypeptide AJ003-37 in Example 3 over time.

[0032] Figure 6 A line graph showing the change in the main peak area of ​​polypeptide AJ003-38 in Example 3 over time.

[0033] Figure 7 The results of the prediction of the in vitro half-life of polypeptide AJ003-39 in human plasma in Example 3 are shown.

[0034] Figure 8 A line graph showing the change in the main peak area of ​​polypeptide AJ003-40 in Example 3 over time.

[0035] Fig. 9 A line graph showing the change in the main peak area of ​​polypeptide AJ003-41 in Example 3 over time.

[0036] Fig.10 A line graph showing the change in the main peak area of ​​polypeptide AJ003-42 in Example 3 over time.

[0037] Fig.11 The mechanical pain threshold on the first day of administration of the same dose of polypeptide in the rat paclitaxel chronic chemotherapy pain model in Example 5 is shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way analysis of variance (n=7-8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance. Pregabalin is 30 mg / kg·d·qd, gavage; AJ003, AJ003-34, AJ003-35, AJ003-36, AJ 003-39 and AJ 003-40 are 1 mg / kg·d·qd, subcutaneous injection.

[0038] Fig.12The mechanical pain threshold on the third day of administration of the same dose of polypeptide in the rat paclitaxel chronic chemotherapy pain model in Example 5 is shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way analysis of variance (n=7-8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance. Pregabalin is 30 mg / kg·d·qd, gavage; AJ003, AJ003-34, AJ003-35, AJ003-36, AJ 003-39 and AJ 003-40 are 1 mg / kg·d·qd, subcutaneous injection.

[0039] Fig.13 The mechanical pain threshold on the 5th day of administration of the same dose of polypeptide in the rat paclitaxel chronic chemotherapy pain model in Example 5 is shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way analysis of variance (n=7-8). Model group and control group: ####p<0.0001; drug administration group and model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance. Pregabalin is 30mg / kg·d·qd, gavage; AJ003, AJ003-34, AJ003-35, AJ003-36, AJ 003-39 and AJ 003-40 are 1mg / kg·d·qd, subcutaneous injection.

[0040] Fig.14 The mechanical pain threshold on the 12th day of administration of the same dose of polypeptide in the rat paclitaxel chronic chemotherapy pain model in Example 5 is shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way analysis of variance (n=7-8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance. Pregabalin is 30 mg / kg·d·qd, gavage; AJ003, AJ003-34, AJ003-35, AJ003-36, AJ 003-39 and AJ 003-40 are 1 mg / kg·d·qd, subcutaneous injection.

[0041] Fig.15The mechanical pain thresholds on the first day after different doses of the polypeptides were administered in the paclitaxel chronic chemotherapy pain model of rats in Example 6 are shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way ANOVA (n=8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: not statistically significant. Pregabalin was 30 mg / kg·d·qd, administered orally; AJ003 was 1 mg / kg·d·qd, administered subcutaneously, AJ003-36-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, AJ003-36-high dose was 1.5 mg / kg·d·qd, administered subcutaneously, AJ003-40-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, and AJ003-40-high dose was 1.5 mg / kg·d·qd, administered subcutaneously.

[0042] Fig.16 The mechanical pain thresholds on the 4th day after different doses of the polypeptides were administered in the paclitaxel chronic chemotherapy pain model of rats in Example 6 are shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (± SD). Graphpad, one-way ANOVA (n = 8). Model group vs. control group: ####p < 0.0001; drug administration group vs. model group: ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns: not statistically significant. Pregabalin was 30 mg / kg·d·qd, administered orally; AJ003 was 1 mg / kg·d·qd, administered subcutaneously, AJ003-36-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, AJ003-36-high dose was 1.5 mg / kg·d·qd, administered subcutaneously, AJ003-40-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, and AJ003-40-high dose was 1.5 mg / kg·d·qd, administered subcutaneously.

[0043] Fig.17The mechanical pain thresholds of different doses of the polypeptides administered in the rat paclitaxel chronic chemotherapy pain model in Example 6 on the 7th day are shown. The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (± SD). Graphpad, one-way ANOVA (n = 8). Model group vs. control group: ####p < 0.0001; drug administration group vs. model group: ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns: not statistically significant. Pregabalin was 30 mg / kg·d·qd, administered orally; AJ003 was 1 mg / kg·d·qd, administered subcutaneously, AJ003-36-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, AJ003-36-high dose was 1.5 mg / kg·d·qd, administered subcutaneously, AJ003-40-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, and AJ003-40-high dose was 1.5 mg / kg·d·qd, administered subcutaneously.

[0044] Fig.18 The mechanical pain thresholds of different doses of the polypeptides administered in the paclitaxel chronic chemotherapy pain model of rats in Example 6 on the 12th day are shown. . The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as the mechanical pain threshold (g) (±SD). Graphpad, one-way ANOVA (n=8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: not statistically significant. Pregabalin was 30 mg / kg·d·qd, administered orally; AJ003 was 1 mg / kg·d·qd, administered subcutaneously, AJ003-36-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, AJ003-36-high dose was 1.5 mg / kg·d·qd, administered subcutaneously, AJ003-40-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, and AJ003-40-high dose was 1.5 mg / kg·d·qd, administered subcutaneously.

[0045] Fig.19The mechanical pain thresholds of different doses of the polypeptides administered in the paclitaxel chronic chemotherapy pain model of rats in Example 6 on the 14th day are shown. . The vertical axis is the mechanical pain threshold, and the horizontal axis is the different groups. The results are shown as mechanical pain threshold (g) (±SD). Graphpad, one-way ANOVA (n=8). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance. Pregabalin was 30 mg / kg·d·qd, administered orally; AJ003 was 1 mg / kg·d·qd, administered subcutaneously, AJ003-36-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, AJ003-36-high dose was 1.5 mg / kg·d·qd, administered subcutaneously, AJ003-40-low dose was 0.5 mg / kg·d·qd, administered subcutaneously, and AJ003-40-high dose was 1.5 mg / kg·d·qd, administered subcutaneously.

[0046] Fig. 20 The change of mechanical pain threshold over time of different doses of the polypeptide administered in the mouse oxaliplatin acute chemotherapy pain model in Example 7 is shown. The results are shown as mechanical pain threshold (g) (± SD). Graphpad, one-way ANOVA (n = 8). Model group vs. control group: ####p < 0.0001; drug administration group vs. model group: ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05; ns: no statistical significance.

[0047] Fig.21 The mechanical pain thresholds of different doses of the polypeptides administered in Example 9 in the rat CCI model on the first day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05; ns: no statistical significance.

[0048] Fig. 22 The mechanical pain thresholds of different doses of the polypeptides administered in the rat CCI model in Example 9 on the 4th day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; **p<0.01; ns: no statistical significance.

[0049] Fig.23The mechanical pain thresholds of different doses of the polypeptides administered in the rat CCI model in Example 9 on the 7th day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; **p<0.01; *p<0.05. ns: not statistically significant.

[0050] Fig.24 The mechanical pain thresholds of different doses of the polypeptides administered in the rat CCI model in Example 9 on the 10th day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. ns: not statistically significant.

[0051] Fig.25 The mechanical pain thresholds of different doses of the polypeptides administered in the rat CCI model in Example 9 on the 14th day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01. ns: not statistically significant.

[0052] Fig.26 The mechanical pain thresholds on the first day after administration of different doses of the polypeptide in the diabetic neuropathy model of mice in Example 10 are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. ns: no statistical significance.

[0053] Fig. 27 The mechanical pain thresholds on the 4th day after administration of different doses of polypeptides in the diabetic neuropathy model of mice in Example 10 are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. ns: no statistical significance.

[0054] Fig.28The mechanical pain thresholds of different doses of polypeptides administered in the diabetic neuropathy model of mice in Example 10 on the 8th day are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. ns: no statistical significance.

[0055] Fig.29 The mechanical pain thresholds at day 14 after administration of different doses of polypeptides in the diabetic neuropathy model of mice in Example 10 are shown. The results are shown as mechanical pain thresholds (g) (±SD). Graphpad, one-way ANOVA (n=7). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01; *p<0.05. ns: no statistical significance.

[0056] Fig.30 The change of mechanical pain threshold over time after administration of different polypeptides in the mouse oxaliplatin acute chemotherapy pain model in Example 8 is shown. The results are shown as mechanical pain threshold (g) (±SD). Graphpad, one-way ANOVA (n=3). Model group vs. control group: ####p<0.0001; drug administration group vs. model group: ****p<0.0001; ***p<0.001; **p<0.01. ns: not statistically significant.

[0057] Fig.31 The HPLC analysis chart of AJ003-40 in Example 4 after incubation in human plasma at 37°C for 0 hours is shown.

[0058] Fig.32 The HPLC analysis profile of AJ003-40 in Example 4 after incubation in human plasma at 37° C. for 24 hours is shown.

[0059] Fig.33 The HPLC analysis chart of AJ003-24 in Example 4 after incubation in human plasma at 37°C for 0 hours is shown.

[0060] Fig.34 The HPLC analysis profile of AJ003-24 in Example 4 after incubation in human plasma at 37°C for 22 hours is shown. DETAILED DESCRIPTION

[0061] Unless otherwise indicated, all numbers used in this specification and claims to indicate content, concentration, ratio, weight, particle size, percentage, technical effect, etc. should be understood as modified by the term "about" or "approximately" in any case. Therefore, unless otherwise indicated, the numerical parameters listed in the following specification and the attached claims are approximate values.

[0062] Unless otherwise stated, the terms used herein have the usual understanding meanings for those skilled in the art. For those skilled in the art, it can vary according to the desired properties and effects sought to be obtained by the application, and each numerical parameter should be interpreted according to the number of significant digits and conventional rounding methods or the manner understood by those skilled in the art. In general, the nomenclature used herein and the experimental operations of organic chemistry, medicinal chemistry, and biology described herein are well known in the art and are generally used in the art. Unless otherwise defined, all technical and scientific terms used herein generally have the same meanings that are commonly understood by those of ordinary skill in the art of the application. In the case where there are multiple definitions of the terms used herein, unless otherwise stated, the definitions of this section shall prevail.

[0063] As used herein, the expression "A and / or B" includes three cases: (1) A; (2) B; and (3) A and B. The expression "A, B, and / or C" includes seven cases: (1) A; (2) B; (3) C; (4) A and B; (5) A and C; (6) B and C; and (7) A, B, and C. The meanings of similar expressions can be deduced analogously.

[0064] As used herein, the term "independently of each other" means that multiple events have no influence on each other. For example, "X and Y are independently selected from any one of a, b, c, d, e, f, and g" means that X can be any one of a, b, c, d, e, f, and g, and Y can also be any one of a, b, c, d, e, f, and g. The selection of X and the selection of Y can be the same or different, and the two do not interfere with each other.

[0065] When used herein, alanine scanning (Cunningham and Wells, Science 244, 1081-1085, 1989) is used to identify amino acids that play a key role in the activity of the peptides of the present invention (e.g., binding affinity to acetylcholine receptors) so that these amino acids are not substituted. Alanine scanning introduces mutations into each residue of the molecule and tests the biological activity of the resulting molecule to determine the amino acid residues that play a key role in the activity of the molecule.

[0066] As used herein, the terms “comprising” and “including” mean that in addition to the listed elements, other elements are not excluded.

[0067] As used herein, the term "identity" refers to the degree to which two (nucleotide or amino acid) sequences have the same residue at the same position in an alignment, and is generally expressed as a percentage. Preferably, identity is determined over the overall length of the sequence being compared. Therefore, two copies with exactly the same sequence have 100% identity. Those skilled in the art will recognize that some algorithms can be used to determine sequence identity using standard parameters, such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197) and Clustal W.

[0068] Peptide or its derivatives

[0069] The present application provides a peptide or a derivative thereof comprising any one sequence selected from SEQ ID NO: 1-34.

[0070] The application provides a peptide or a derivative thereof comprising any one of the sequences selected from SEQ ID NO: 1-34 with conservative substitutions. In some embodiments, any one of SEQ ID NO: 1-34 with conservative substitutions has 1, 2, 3, 4 or 5 conservative substitutions. In some embodiments, any one of SEQ ID NO: 1-34 with conservative substitutions has at least 65% sequence identity, at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity or at least 95% sequence identity with a sequence without conservative substitutions.

[0071] The present application provides a peptide or a derivative thereof comprising the following formula I or a conservatively substituted formula I in order from N-terminus to C-terminus,

[0072] Gly-Ser-Cys-Ser-X1-X2-X3-X4-(D-Cys)-X5-X6-X7-X8 Formula I

[0073] The 3rd Cys and the 9th D-Cys in Formula I form a pair of intramolecular disulfide bonds, D-Cys represents D-cysteine, "-" between amino acid residues represents a peptide bond, the C-terminus of the peptide or its derivative is a free carboxyl group or an amide, and X1 is Thr or D-Thr, X5 is selected from any one of Ala, Val and D-Val, and X2-X4 and X6-X8 are independently any one of amino acids.

[0074] In some embodiments, X1 in Formula I is Thr or D-Thr. In some embodiments, X5 in Formula I is selected from any one of Ala, Val and D-Val. In some embodiments, X2 in Formula I is selected from any one of Pro, D-Pro and Hyp. In some embodiments, X3 in Formula I is selected from any one of Pro, D-Pro and Hyp. In some embodiments, X4 in Formula I is selected from any one of Ser, D-Ser, Ala and Aib. In some embodiments, X6 in Formula I is selected from any one of Ala, Leu, D-Leu, Ile, ABu and Nle. In some embodiments, X7 in Formula I is selected from any one of Tyr, D-Tyr, Ala, Trp, Phe and Bip. In some embodiments, X8 in Formula I is selected from any one of Ser, D-Ser, Ala, and Orn.

[0075] In some embodiments, the above-mentioned Formula I with conservative substitutions has 1, 2, 3, 4 or 5 amino acid conservative substitutions. In one embodiment of the present disclosure, the above-mentioned Formula I with conservative substitutions has at least 65% sequence identity, at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity or at least 95% sequence identity with Formula I without conservative substitutions.

[0076] In some embodiments, the peptide or its derivative comprises any one of the following sequences: SEQ ID NO: 1-5, SEQ ID NO: 10-16 and SEQ ID NO: 20-34, SEQ ID NO: 1-5, SEQ ID NO: 10-16 and SEQ ID NO: 20-34 with conservative substitutions. In some preferred embodiments, the peptide or its derivative comprises SEQ ID NO: 26 or SEQ ID NO: 26 with conservative substitutions. In some preferred embodiments, the peptide or its derivative comprises SEQ ID NO: 28 or SEQ ID NO: 28 with conservative substitutions. In some preferred embodiments, the peptide or its derivative comprises SEQ ID NO: 32 or SEQ ID NO: 32 with conservative substitutions.

[0077] In some embodiments, the above-mentioned sequence with conservative substitutions has 1, 2, 3, 4 or 5 amino acid conservative substitutions. In some embodiments, the above-mentioned sequence with conservative substitutions has at least 65% sequence identity, at least 70% sequence identity, at least 75% sequence identity, at least 80% sequence identity, at least 84% sequence identity, at least 85% sequence identity, at least 90% sequence identity, at least 92% sequence identity or at least 95% sequence identity with the sequence without conservative substitutions.

[0078] In some embodiments, the derivative comprises any one or more modifications selected from the following compared to the peptide: amino acid modification, conservative amino acid substitution, and substitution of hydrogen in an amino acid residue.

[0079] When used in this article, the term "peptide" refers to a compound formed by amino acids linked together with peptide bonds. A peptide composed of three or more amino acid molecules is a polypeptide. When used in this article, unless otherwise specified or contradictory to the context, the term "peptide" covers the peptide itself and its pharmaceutically acceptable salts, prodrugs and metabolites mentioned. The peptides of the present application are generated by conventional technical means in the art, including but not limited to solid phase synthesis (such as Fmoc peptide synthesis) and liquid phase synthesis.

[0080] When used in this article, the position numbering of a polypeptide or its derivative is carried out in order from the N-terminus to the C-terminus, for example, the first amino acid starting from the N-terminus of the peptide is the first amino acid, the second amino acid starting from the N-terminus of the peptide is the second amino acid, the third amino acid starting from the N-terminus of the peptide is the third amino acid, and so on.

[0081] Unless otherwise defined, as generally understood in the art, the left-hand end of an amino acid sequence or polypeptide sequence is the N-terminus / amino terminus, and the right-hand end of an amino acid sequence or polypeptide sequence is the C-terminus / carboxyl terminus. As used herein, the term "prodrug" refers to all molecules that are converted into the peptides of the present disclosure or their derivatives by reactions such as oxidation, reduction, hydrolysis, etc., carried out in vivo under physiological conditions, such as by the action of enzymes, gastric acid, etc.

[0082] As used herein, the term "metabolites" refers to all molecules in a cell or organism (preferably a human) derived from a peptide of the present disclosure or a derivative thereof.

[0083] When used in this article with respect to peptides, "amino acid" and "amino acid residue" have the same meaning, which means that when amino acids are connected by chemical bonds, part of their groups are lost due to participation in the formation of the connecting bonds, and the remaining amino acid part is the amino acid residue.

[0084] As used herein, the names and abbreviations of amino acids correspond to the following:

[0085]

[0086]

[0087] Natural amino acids, except glycine, all contain chiral carbon atoms. Unless otherwise specified, the optically active amino acids described in this application are all in the L-configuration. As usual, the structure of the peptides herein is written with the amino terminus (N-terminus) on the left and the carboxyl terminus (C-terminus) on the right.

[0088] The term "amino acid" as used herein includes the natural amino acids, as well as other "non-protein" α-amino acids / unnatural amino acids commonly used in the art of peptide chemistry to prepare analogs of natural peptides.

[0089] Natural amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamic acid, glutamine, arginine, ornithine and lysine. Examples of "non-protein" α-amino acids / unnatural amino acids are norleucine, norvaline, alloisoleucine, homoarginine, thioproline, dehydroproline, hydroxyproline (Hyp), homoserine, cyclohexylglycine (Chg), α-amino-n-butyric acid (Aba), cyclohexylalanine (Cha), aminophenylbutyric acid (Pba), phenylalanine substituted in the phenyl moiety by alkyl, alkoxy, halogen or nitro, O-alkylated derivatives of serine, threonine and tyrosine, S-alkylated cysteine, O-sulfate esters of tyrosine, and the D-isomers of the natural amino acids.

[0090] As used herein, a "derivative" of a peptide refers to a product obtained by amino acid modification, conservative amino acid substitution and / or replacement of hydrogen in an amino acid residue based on the peptide.

[0091] As used herein, the term "amino acid modification" includes, but is not limited to, N-terminal modification, C-terminal modification, and side chain modification. The methods of "amino acid modification" include, but are not limited to, hydroxylation, carboxylation, alkylation, acylation, phosphorylation, sulfonation, amidation, aldehyde modification, alcoholization, mercaptoethylation, esterification, glycosylation, and the like.

[0092] As used herein, "conservative amino acid substitution" can generally be described as an amino acid residue being replaced by another amino acid having a similar chemical structure and / or similar chemical properties, and having little effect on the function, activity or other biological properties of the peptide. Such conservative amino acid substitutions are well known in the art. Such conservative substitutions can be, for example, an amino acid in the following groups (a)-(e) being replaced by another amino acid in the same group: (a) small aliphatic, non-polar or weakly polar amino acid residues: Ala, Ser, Thr, Pro and Gly; (b) negatively charged polar amino acid residues and their amides: Asp, Asn, Glu and Gln; (c) positively charged polar amino acid residues: His, Arg and Lys; (d) large aliphatic, non-polar amino acid residues: Met, Leu, Ile, Val and Cys; (e) aromatic amino acid residues: Phe, Tyr and Trp.

[0093] As used herein, the replacement of hydrogen in an amino acid residue may be that the hydrogen in the amino acid residue is replaced by any conventional substituent known in the art, including but not limited to alkyl, alkenyl, alkynyl, aromatic, alkoxy, carboxyl, aldehyde, carbonyl, hydroxyl, halogen, cyano, acyl, sulfonic acid, amino, thiol or nitro groups and the like.

[0094] Polynucleotides, expression vectors, host cells

[0095] The present application provides a polynucleotide encoding the peptide or its derivatives described in the present disclosure.

[0096] As used herein, "polynucleotide" refers to a polymer of nucleotides (nucleotides or deoxynucleotides) of any length. The term refers to the primary structure of the molecule. It thus includes both double-stranded and single-stranded RNA, and double-stranded and single-stranded DNA. It also includes polynucleotides modified, such as by methylation and / or end-capping, and unmodified forms of polypeptide nucleotides. The polynucleotides described herein are not necessarily obtained by physical methods, but may be produced in any manner, including, for example, chemical synthesis or DNA replication, reverse transcription or transcription.

[0097] The present application provides an expression vector, which can express the polynucleotide described in the present disclosure.

[0098] The present application provides a host cell, which comprises the polynucleotide described in the present disclosure or the expression vector described in the present application.

[0099] As used herein, "host cells" are cells that serve as recipients for expression vectors or other transformed genetic segments. They include the original cell that has been transfected and its progeny. Host cells include prokaryotes, yeast or other eukaryotic cells.

[0100] Pharmaceutical composition

[0101] The present application provides a pharmaceutical composition comprising the peptide or its derivative described in the present disclosure, and a pharmaceutically acceptable carrier or salt.

[0102] The present application also provides a pharmaceutical composition, which comprises the peptide or its derivative, polynucleotide, expression vector or host cell according to the present disclosure, and a pharmaceutically acceptable carrier or salt thereof.

[0103] As used herein, the term "pharmaceutical composition" refers to a mixture of the peptides of the present disclosure and other chemical components such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners and / or excipients. Pharmaceutical compositions facilitate administration of the peptides to an organism. There are a variety of ways to administer peptides in the art, including, but not limited to, subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intrathecal injection, oral, transdermal, pulmonary, ocular and topical administration.

[0104] In the present application, the pharmaceutical composition can be configured as a dosage form suitable for administration to a subject via a desired route of administration. The dosage form includes, but is not limited to, tablets, capsules, caplets, pills, lozenges, powders, syrups, brews, suspensions, solutions, emulsions, transdermal patches, suppositories, inhalants, creams, ointments, lotions, pastes, sprays, freeze-dried, injections, and gels.

[0105] As used herein, the term "pharmaceutically acceptable salts" includes acid addition salts and base addition salts. Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include, but are not limited to, acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, cyclaminate, edisylate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, 2-(4-hydroxybenzyl)benzoate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, 2-hydroxyethanesulfonate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthoate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, hexadecanoate, phosphate / hydrogenphosphate / dihydrogenphosphate, pyroglutamate, glucarate, stearate, salicylate, tannate, tartrate, toluenesulfonate, and trifluoroacetate. Suitable base addition salts are formed from bases which form non-toxic salts. Examples include, but are not limited to, aluminum, arginine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts. Hemi-salts of acids and bases, such as hemisulphate and hemicalcium salts, can also be formed. For a review of suitable salts, see Handbook of Pharmaceutical Salts: Properties, Selection and Use by Stahland Wermuth (Wiley-VCH, 2002).

[0106] The term "pharmaceutically acceptable carrier" includes pharmaceutically acceptable materials, compositions or vehicles, such as liquid or solid fillers, diluents, excipients, solvents or encapsulating materials, which are involved in carrying or transporting the peptides of the present disclosure within a subject or carrying or transporting the peptides of the present disclosure to a subject so that it can perform its intended function. Each salt or carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject. Some examples of materials that can be used as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerol, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate; Esters and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; phosphate buffered solution; diluents; granulating agents; lubricants; binders; disintegrants; wetting agents; emulsifiers; colorants; release agents; coating agents; sweeteners; flavoring agents; perfuming agents; preservatives; antioxidants; plasticizers; gelling agents; thickeners; hardeners; fixatives; suspending agents; surfactants; humectants; carriers; stabilizers; and other nontoxic, compatible substances used in pharmaceutical preparations, or any combination thereof.

[0107] Uses, disease treatment methods

[0108] The present application provides use of the peptide or its derivative described in the present disclosure or the pharmaceutical composition described in the present disclosure in the preparation of a drug for treating pain.

[0109] The present application also provides use of the peptide or derivatives thereof described in the present disclosure, the polynucleotide described in the present disclosure, the expression vector described in the present disclosure, the host cell described in the present disclosure or the pharmaceutical composition described in the present disclosure in the preparation of a drug for treating pain.

[0110] In some embodiments, the medicine for treating pain prepared is administered by subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intrathecal injection, oral administration, transdermal administration, pulmonary administration, ocular administration or topical administration. In a preferred embodiment, the medicine for treating pain prepared is administered by subcutaneous injection.

[0111] In some embodiments, the pain includes pain caused by acting on nicotinic acetylcholine receptors. In some embodiments, the pain includes neuralgia and inflammatory pain. In some embodiments, the pain includes pain caused by chemotherapy, diabetic peripheral neuropathy, sciatica, bone and joint pain, postherpetic neuralgia, infection pain, nutritional deficiency pain, inflammatory pain, chronic alcoholism pain, hypothyroidism pain, autoimmune disease pain, Guillain-Barre syndrome pain, poisoning pain, drug-induced pain, tumor lesions pain, genetic disease pain and contusion pain.

[0112] The present application further provides the peptide or derivative thereof described in the present disclosure, the polynucleotide described in the present disclosure, the expression vector described in the present disclosure, the host cell described in the present disclosure or the pharmaceutical composition described in the present disclosure, for use in treating pain.

[0113] In some embodiments, the pain includes pain caused by acting on nicotinic acetylcholine receptors. In some embodiments, the pain includes neuralgia and inflammatory pain. In some embodiments, the pain includes pain caused by chemotherapy, diabetic peripheral neuropathy, sciatica, bone and joint pain, postherpetic neuralgia, infection pain, nutritional deficiency pain, inflammatory pain, chronic alcoholism pain, hypothyroidism pain, autoimmune disease pain, Guillain-Barre syndrome pain, poisoning pain, drug-induced pain, tumor lesions pain, genetic disease pain and contusion pain.

[0114] In some embodiments, the peptide or its derivative or pharmaceutical composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intrathecal injection, oral administration, transdermal administration, pulmonary administration, ocular administration or topical administration. In a preferred embodiment, the peptide or its derivative or pharmaceutical composition is administered by subcutaneous injection.

[0115] The present application provides a method for treating pain, which comprises administering a therapeutically effective amount of the peptide or derivative thereof according to the present disclosure or the pharmaceutical composition according to the present disclosure to a subject in need thereof.

[0116] The present application also provides a method for treating pain, which comprises administering a therapeutically effective amount of the peptide or its derivative, polynucleotide, expression vector, host cell according to the present disclosure or the pharmaceutical composition according to the present disclosure to a subject in need thereof.

[0117] In some embodiments, the pain includes pain caused by acting on nicotinic acetylcholine receptors. In some embodiments, the pain includes neuralgia and inflammatory pain. In some embodiments, the pain includes pain caused by chemotherapy, diabetic peripheral neuropathy, sciatica, bone and joint pain, postherpetic neuralgia, infection pain, nutritional deficiency pain, inflammatory pain, chronic alcoholism pain, hypothyroidism pain, autoimmune disease pain, Guillain-Barre syndrome pain, poisoning pain, drug-induced pain, tumor lesions pain, genetic disease pain and contusion pain.

[0118] In some embodiments, the peptide or its derivative or pharmaceutical composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intrathecal injection, oral administration, transdermal administration, pulmonary administration, ocular administration or topical administration. In a preferred embodiment, the peptide or its derivative or pharmaceutical composition is administered by subcutaneous injection.

[0119] As used herein, the term "subject" includes animals, such as vertebrates, preferably mammals, such as dogs, cats, pigs, cows, sheep, horses, rodents (e.g., mice, rats, or guinea pigs), or primates (e.g., gorillas, chimpanzees, and humans).

[0120] As used herein, the term "treat" refers to alleviating or ameliorating a disease or disorder (i.e., slowing or arresting the development of the disease or at least one clinical symptom); or alleviating or ameliorating at least one physical parameter or biomarker associated with the disease or disorder.

[0121] As used herein, the term "therapeutically effective dose" refers to an amount that results in benefit or treatment of a disease compared to a corresponding subject that has not received the amount, but the amount is sufficiently low within the scope of reasonable medical judgment to avoid serious side effects. The therapeutically effective dose of the peptide or its derivative, polynucleotide, expression vector, host cell or pharmaceutical composition described herein will vary with the selected peptide or its derivative, polynucleotide, expression vector, host cell or pharmaceutical composition; route of administration; severity of the disease being treated; age, size, weight and physical condition of the patient being treated: medical history of the patient being treated; duration of treatment; nature of concurrent treatment; desired therapeutic effect and other factors, but can still be determined by those skilled in the art in a routine manner.

[0122] The various embodiments described above for the peptides or their derivatives, polynucleotides, expression vectors and host cells of the present disclosure are also applicable to the pharmaceutical compositions, uses and methods of the present disclosure (as long as they are not inherently contradictory to each other), and the various embodiments formed by such combination are considered to be part of the present disclosure.

[0123] Example

[0124] The following is a description of exemplary embodiments of the present application in conjunction with the accompanying drawings, including various details of the embodiments of the present application to facilitate understanding. It should be understood that they are considered to be merely exemplary and are by no means intended to limit the scope of protection of the present application. The scope of protection of the present application is limited only by the claims. Therefore, it should be recognized by those of ordinary skill in the art that various changes and modifications can be made to the embodiments described herein without departing from the scope of the present application. Similarly, for clarity and conciseness, the description of well-known functions and structures is omitted in the following description.

[0125] Unless otherwise specified, the reagents and instruments used in the following examples are all commercially available conventional products. Unless otherwise specified, the experiments were performed under conventional conditions or conditions recommended by the manufacturer.

[0126] Example 1: Synthesis of conotoxin polypeptide

[0127] Based on the previous research, a group of polypeptide compounds were preliminarily screened by performing alanine scanning, single-site non-natural amino acid substitution and multi-site combination modification on the parent peptide AJ003.

[0128] Synthesis of AJ003: Fmoc-Ser(tBu)-wang resin (Tianjin Nankai Synthesis Technology Co., Ltd.) was used as the starting resin, with a synthesis scale of 1 mmol. The resin was weighed and added to a polypeptide solid phase reactor (Nanjing Luanyu Chemical Glass Instrument Co., Ltd.), and dichloromethane nitrogen was added to swell for 30 minutes, and then washed twice with DMF (dimethylformamide). 20% piperidine / DMF solution was added twice, and the reaction lasted for 5 minutes each time. After the deprotection reaction was completed, the resin was washed with DMF 6 times, each time for about 3 minutes. According to the polypeptide sequence, the principle that the conventional chemical synthesis of polypeptides is to couple amino acids one by one from the C-terminus to the N-terminus was followed. The corresponding protected amino acids and condensation reagents (HoBt, DIC) were weighed, and the reaction was about 1 hour. After the condensation reaction was completed, the resin was washed with DMF 3 times. From then on, a condensation cycle (deprotection-washing-condensation-washing) was carried out, that is, 20% piperidine / DMF solution was added to the reaction vessel again to carry out the deprotection reaction. After washing with DMF, the protected amino acids and the corresponding condensation reagents were added to carry out the condensation reaction. The protected amino acids are coupled to the N-terminus one by one by using the condensation cycle method until all the amino acids of the polypeptide are coupled. The Fmoc group at the N-terminus of the polypeptide is removed with a 20% piperidine / DMF solution, and the resin is alternately washed with dichloromethane and methanol, and finally a shrink-dried peptide resin intermediate is obtained by vacuum drying. The peptide resin is weighed and a lysis solution is prepared according to the ratio of 1 gram of peptide resin to 10 ml of lysis solution. The lysis solution formula is TFA:EDT:TIS:H2O=90:5:2.5:2.5. The lysis solution is added to the peptide resin, and the lysis reaction is carried out for about 3 hours. Finally, the filtrate is collected and the filtrate is precipitated with frozen methyl tert-butyl ether. The amount of methyl tert-butyl ether used is 8 times that of the filtrate. The precipitate is fully stirred and centrifuged in a cup to obtain a crude peptide precipitate. The methyl tert-butyl ether is continued to be washed and centrifuged, and the precipitate is vacuum dried overnight to finally obtain a linear crude peptide sample. After the linear crude peptide is dissolved in water, iodine is added as an oxidant to oxidize the polypeptide into a disulfide bond. The oxidation was carried out for about 30 minutes, and the degree of oxidation was monitored by HPLC. Finally, vitamin C was added to the oxidation system to terminate the oxidation reaction. The oxidized polypeptide solution was filtered with a filter membrane, separated and purified by reversed-phase high-performance liquid chromatography, and the qualified fractions were combined and finally freeze-dried using a freeze dryer to obtain the pure freeze-dried polypeptide.

[0129] The synthesis methods of other polypeptides are consistent with the technical route of the above-mentioned polypeptide AJ003, and the classic Fmoc solid phase peptide synthesis technology is used to obtain linear crude peptides. For polypeptides with amide ending at the C-terminus of the polypeptide sequence, the resin used is Rink amide-MBHA resin. The crude peptide liquid is oxidized by iodine to form a disulfide bond polypeptide fraction, which is then separated and purified by reversed-phase high performance liquid chromatography technology, and finally a freeze-dried pure product is obtained by freeze drying technology. The peptide sequences involved in this embodiment are shown in Table 1.

[0130] Table 1. Summary of peptide sequences

[0131]

[0132]

[0133] *D-Thr: D-threonine; 3,9 disulfide bond: a disulfide bond is formed between the third and ninth amino acid residues in the sequence.

[0134] Example 2: BLI (biofilm interferometry) detection of peptide-target protein affinity

[0135] BLI is a label-free technology that converts the optical interference signal occurring on the surface of the BLI biosensor into a real-time response signal. Through real-time monitoring of the molecular binding process, the system will determine the binding constant (ka or kon) and dissociation constant (kd or koff), as well as the initial binding rate, and obtain the affinity (K D ). The specific steps are to place the NTA sensor (Sartorius) in a pre-wet box, place the pre-wet box in a black 96-well plate, add 200μL of PBS to each well, and pre-wet the NTA sensor for at least 15 minutes. Dilute the target protein α9nAChR with PBS to 5μg / mL, and add 200μL to each well. The peptide to be tested is dissolved in PBS and diluted 3 times in a gradient, and the concentrations are 1000nM, 333.3nM, 111.1nM, 37.04nM, 12.35nM, 4.115nM, 1.372nM from high to low, and finally add a PBS well as a zero concentration control well. After balancing the instrument baseline, the target protein α9nAChR is first solidified using the NTA sensor, and the solidification is completed and the baseline is re-balanced, followed by a 5min binding and 5min dissociation process. According to the above process, the affinity of the peptides to be tested is tested one by one. The affinity detection process between the peptide and the target protein α7nAChR is basically the same as that of α9nAChR, except that the protein concentration of the target protein α7nAChR is 20μg / mL. As shown in Tables 2 and 3 below, the BLI experiment detected the affinity of the alanine scanning peptide analogue with the target protein, and clarified the reconfigurable site of the parent peptide; secondly, the BLI experiment was used to detect the affinity of the single-site non-natural amino acid mutation modified peptide with the target protein; finally, the BLI experiment was used to detect the affinity of the multi-site combination mutation modified peptide with the target protein, thereby screening out peptides with high affinity to the target protein for subsequent screening and research on its drugability.

[0136] Table 2. Affinity test results of modified peptides and α9nAChR target protein

[0137]

[0138] Table 3. Affinity test results of modified peptides and α7nAChR target protein

[0139]

[0140] Example 3: Prediction of polypeptide half-life by in vitro plasma stability

[0141] Peptides usually have a short half-life and are easily degraded by various enzymes and matrices in the blood in animals. In the design of the modified peptides in this study, non-natural amino acids were replaced with certain inactive key site amino acids, hoping to improve the stability of the peptide and make it more conducive to drug development. Weigh the peptide and dissolve it in deionized water to 2 mg / mL, then dilute it with acetonitrile to 1 mg / mL and filter it with an organic filter membrane. Draw 200 microliters of the filtrate into a liquid phase vial as a peptide control group. Draw 300 microliters of human plasma (containing EDTA anticoagulant) (Nanjing Senbeijia Biotechnology Co., Ltd., batch number SBJ-P-HU011-100 mL) and add it to 300 microliters of acetonitrile, place it in a centrifuge at 4°C, 12,000 rpm, and centrifuge for 5 minutes. Draw the supernatant and filter it with an organic filter membrane, and draw 200 microliters of the filtrate into a liquid phase vial as a plasma blank control group. Weigh 10 mg of the peptide, add 5 mL of human plasma and vortex mix, draw 300 μL of plasma containing the peptide and add it to 300 μL of acetonitrile, place in a centrifuge at 4°C, 12,000 rpm, centrifuge for 5 minutes, draw the supernatant and filter with an organic filter membrane, draw 200 μL of the filtrate into a liquid phase vial as the peptide 0 min time point sample. Incubate the plasma with the dissolved peptide in a 37°C water bath, and operate the other time points in the same way as the 0 min time point. The sampling points of peptides AJ003 and AJ003-1 were 0min, 5min, 10min, 20min, 30min, 1h, 2h, 4h, 6h, 10h, 12h, and 24h, and the sampling points of modified peptides AJ003-34, AJ003-35, AJ003-36, AJ003-37, AJ003-38, AJ003-39, AJ003-40, AJ003-41, and AJ003-42 were 0min, 10min, 30min, 1h, 4h, 6h, 10h, 12h, and 24h. The series of samples of each peptide were handed over to the analysis department for HPLC analysis, and the changes of the main peak area of ​​the samples with the plasma incubation time were recorded. The in vitro half-life of each peptide was predicted in the pharmacokinetic processing software winolin. Due to the existence of tautomers, the peak area of ​​the AJ003 sample was not easy to accurately integrate and compare over time. AJ003-1 is an analog of AJ003 polypeptide in which the 5th threonine is restructured into D-threonine. The peptide sequence of AJ003-1 differs from that of AJ003 by only one amino acid configuration. Figure 1-10As shown, the in vitro plasma half-life of AJ003-1 is about 10.8h, and the in vitro plasma half-lives of modified peptides AJ003-34, AJ003-35, AJ003-36, AJ003-37, AJ003-38, AJ003-39, AJ003-40, AJ003-41, and AJ003-42 are 61.9h, 45.3h, 65.3h, 71.0h, 26.7h, 43.0h, 84.0h, 30.0h, and 61.4h, respectively. Overall, through the mutation of non-natural amino acids, the in vitro plasma stability of other modified peptides in this project has been significantly improved compared with AJ003-1 (which only differs from AJ003 by one amino acid).

[0142] Example 4: Plasma stability test of AJ003-40 and AJ003-24

[0143] Weigh the peptides AJ003-40 and AJ003-24, add human plasma to them and vortex to mix, and prepare them to 2mg / ml. Take 300 microliters of plasma containing peptides and add them to 300 microliters of acetonitrile, place them in a centrifuge at 4°C, 12000 rpm, centrifuge for 5 minutes, take the supernatant and filter it with an organic filter membrane, and take 200 microliters of the filtrate to a liquid phase vial as a peptide 0 hour time point sample. Place the plasma with dissolved peptides in a 37°C water bath for incubation. Peptide AJ003-40 takes 300 microliters of plasma containing peptides at the 24 hour time point and adds them to 300 microliters of acetonitrile, places them in a centrifuge at 4°C, 12000 rpm, centrifuge for 5 minutes, take the supernatant and filter it with an organic filter membrane, and take 200 microliters of the filtrate to a liquid phase vial as a peptide 24 hour time point sample. Peptide AJ003-24 was prepared by taking 300 μl of plasma containing peptides at the 22-hour time point and adding it to 300 μl of acetonitrile. The mixture was centrifuged at 4°C, 12,000 rpm, and centrifuged for 5 minutes. The supernatant was taken and filtered with an organic filter membrane. 200 μl of the filtrate was taken into a liquid phase vial as the peptide sample at the 22-hour time point. The two peptide samples at 0 and 24 hours were analyzed by HPLC. Fig.31 and Fig.32 As shown, the main peak area of ​​peptide AJ003-40 decreased from 15149.38 at 0 hours to 11829.51 at 24 hours, and the main peak area degradation rate was 21.9% within 24 hours; Fig.33 and Fig.34 As shown, the main peak area of ​​polypeptide AJ003-24 decreased from 746.80 at 0 hours to 267.45 at 22 hours, and the main peak area degradation rate was 64.2% within 22 hours. Compared with polypeptide AJ003-40, polypeptide AJ003-24 has a faster degradation rate, indicating that AJ003-24 has poorer plasma stability than AJ003-40.

[0144] Example 5: Evaluation of the analgesic activity of some modified peptides at the same dose in vivo during paclitaxel chemotherapy

[0145] 180-200g SPF (Specific Pathogen Free) grade SD male rats (Experimental Animal Management Department of Shanghai Institute of Family Planning Science) were weighed on the day of modeling, and the basic pain threshold of the rats was detected by mechanical stimulation. Animals with large differences in weight and pain threshold were eliminated, and the remaining rats were modeled according to the experimental protocol. Paclitaxel powder was dissolved in olive oil to 1 mg / mL, and each rat was injected intraperitoneally at a dose of 2 mg / kg each time. During the entire modeling period, a total of 4 injections were given, with intraperitoneal injections performed on days 1, 3, 5, and 7. Negative control or blank control group rats were injected with the above-mentioned solvent for dissolving paclitaxel. According to literature reports, this model was calculated from the beginning of modeling, and the pain threshold decreased significantly after about 15 days, indicating that a stable rat paclitaxel chronic chemotherapy pain model was successfully constructed. Drug treatment was carried out according to the administration method set in the experimental protocol, as shown in Table 4 below. The blank group in Table 4 represents a group without pain modeling, and the model group represents a group with pain modeling but no drug administration. The rats were medicated at fixed times on the 1st, 3rd, 5th, and 12th days. The soles of the right hind limbs of the rats were stimulated with flat-tip needles 1h, 2.5h, 4h, and 5.5h after the administration of the drug on the 1st, 3rd, and 5th days, and the pain threshold of the rats to mechanical stimulation at the corresponding time points was tested. On the 12th day of administration, the pain threshold of the rats to mechanical stimulation was tested 4h and 7h after the administration of the drug on the same day. Figure 11-14As shown in the figure, based on the experimental results of 4 times of administration, the mother peptide AJ003 has significant analgesic activity in this model within 4 hours compared with the model group, and the analgesic activity after 4 hours is not significant compared with the model group. Among the 5 candidate modified peptides (AJ003-34, AJ003-35, AJ003-36, AJ003-39, AJ003-40), AJ003-34, AJ003-36, and AJ003-40 are the three best analgesic candidates. From the analysis of the results at 7 hours on the 12th day, the analgesic activity of AJ003-36 and AJ003-40 lasts longer, which can last up to 7 hours. In addition, the analgesic activity of this modified peptide is slightly better than that of pregabalin at some administration time points compared with the positive drug. Overall, it is equivalent to the analgesic efficacy of the positive drug pregabalin. AJ003-36 and AJ003-40 can be used as candidate molecules for further study. Paclitaxel is a small molecule chemotherapy drug widely used in clinical practice. While it has anti-tumor effects, it also causes neuralgia in many cancer patients due to its own damage to the patient's nervous system. The chronic chemotherapy pain model of SD male rats induced by multiple low-dose intraperitoneal injections of paclitaxel simulates the analgesic effects of 5 modified peptides, the parent peptide AJ003, and the positive drug pregabalin in this model. The experimental results show that the mechanical pain threshold of the plantar right hind limb of the rat was detected at the corresponding time point after each administration. The overall analysis can preliminarily screen AJ003-36 and AJ003-40 as candidate molecules for further study.

[0146] Table 4. Paclitaxel chemotherapy pain model screening of analgesic activity of some modified peptides at the same dose

[0147]

[0148] Example 6: Evaluation of the analgesic activity of modified peptides at different doses during paclitaxel chemotherapy

[0149] Purchase 180-200g SPF grade SD male rats (Experimental Animal Management Department of Shanghai Institute of Family Planning Science), feed adaptively for about a week, weigh rats on the day of modeling, and detect rat basal pain threshold with mechanical stimulation, remove animals with large differences in weight and pain threshold, and the remaining rats carry out modeling according to the experimental scheme. Paclitaxel powder is dissolved in olive oil to 1mg / mL, and each rat is injected intraperitoneally at 2mg / kg each time. During the whole modeling period, a total of 4 injections are injected, and intraperitoneal injections are performed on days 1, 3, 5, and 7 respectively. Negative control or blank control group rats are injected with the solvent of the above-mentioned dissolution of paclitaxel. According to literature reports, this model is calculated from the beginning of modeling, and the pain threshold has decreased significantly after about 15 days, indicating that the stable rat paclitaxel chronic chemotherapy pain model has been successfully constructed. Drug treatment is carried out according to the administration method set in the experimental scheme, as shown in Table 5 below. Starting from the 15th day after modeling, the animals were treated with medication every day, and the soles of the right hind limbs of the rats were stimulated with flat-head needles 2h, 4h, 6h, and 8h after medication on the 1st, 4th, 7th, 12th, and 14th days to detect the pain threshold of the rats to mechanical stimulation at the corresponding time points. Figure 15-19 . Based on the experimental results of 5 administration treatments, the mother peptide AJ003 has significant analgesic activity in this model within 4 hours compared with the model group, and the analgesic activity is not significant compared with the model group after 4 hours. The two candidate modified peptides AJ003-36 and AJ003-40, whose low-dose analgesic activity of 0.5 mg / kg is equivalent to the analgesic effect of 1 mg / kg of the mother peptide AJ003, are better than the mother peptide AJ003 at the corresponding time points on some administration days. The two candidate modified peptides AJ003-36 and AJ003-40, whose high-dose analgesic activity of 1.5 mg / kg is slightly better than the positive drug pregabalin, and the analgesic effect still has significant analgesic activity compared with the model group 8 hours after administration.

[0150] Table 5. Dosage schedule for analgesic activity of some modified peptides at different doses in the paclitaxel chemotherapy pain model

[0151]

[0152] Example 7: Evaluation of the analgesic activity of candidate modified peptides at different doses in vivo for pain induced by oxaliplatin chemotherapy

[0153] Oxaliplatin was dissolved in 5% glucose solution to 1 mg / mL. Each C57 male mouse in the modeling group (Hangzhou Ziyuan Experimental Animal Technology Co., Ltd.) was injected intraperitoneally with a single dose of 10 mg / kg of oxaliplatin. The negative control or blank control group was injected with 5% glucose solution. The mechanical pain threshold of the mice was tested about one week after modeling. The pain threshold of each mouse was measured 3 times, and the average value was calculated. The mice were randomly divided according to the pain threshold. The mice were administered drugs according to the dosing schedule in Table 6 (a total of 1 dose), and the mechanical pain threshold was tested at 0.5, 1, 2, 4, 6, and 8 h after administration. Fig. 20 As shown in the figure, at the four time points of 0.5h, 1h, 2h, and 4h after administration, the three low, medium, and high dose groups of the positive drug pregabalin, the parent peptide AJ003, and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h, the parent peptide AJ003 was not significant compared with the model group, and the low, medium, and high dose groups of the positive drug and modified peptide AJ003-36 still had significant analgesic activity compared with the model group. At 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the medium and high dose groups of the positive drug and modified peptide still had significant analgesic activity compared with the model group.

[0154] Table 6. Oxaliplatin chemotherapy pain medication schedule

[0155]

[0156] Example 8: Evaluation of the analgesic activity of various peptides in vivo for pain induced by oxaliplatin chemotherapy

[0157] Oxaliplatin was dissolved in 5% glucose solution to 1 mg / mL. Each C57 male mouse in the modeling group (Shanghai Bikekeyi Biotechnology Co., Ltd.) was injected intraperitoneally with a single dose of 10 mg / kg of oxaliplatin. The negative control or blank control group was injected with 5% glucose solution. The mechanical pain threshold of the mice was tested about one week after modeling. The pain threshold of each mouse was measured 3 times, and the average value was calculated. The mice were randomly divided according to the pain threshold. The mice were administered drugs according to the dosing schedule in Table 7 (a total of 1 dose), and the mechanical pain threshold was tested at 0.5, 1, 2, 4, 6, and 8 h after administration. Fig.30 As shown, starting from 0.5h after administration, the mechanical pain threshold of mice in the AJ003-36 administration group was significantly lower than that in the model group, and there was a significant difference, while the AJ003-24 and AJ003-25 administration groups did not reduce the mechanical pain threshold of mice. This indicates that the peptide AJ003-36 can effectively relieve the chemotherapy pain of mice caused by oxaliplatin, while the peptides AJ003-24 and AJ003-25 cannot relieve the pain.

[0158] Table 7. Drug administration table for the mouse oxaliplatin chemotherapy pain model experiment

[0159]

[0160] Example 9: Evaluation of the analgesic activity of candidate modified peptides at different doses in rat CCI model

[0161] There are many types of neuropathic pain, and animal models can be used to simulate clinical neuropathic pain. The sciatic nerve pathological pain models of SD rats mainly include CCI (chronic compression injury model), SNI (SNI model of selective ligation of sciatic nerve branches), SNL (SNL model of selective ligation of spinal nerves), and CCD (using stainless steel wire to pass through the intervertebral foramen to fix and compress the dorsal root ganglia). Among them, the CCI model modeling method has been widely used in the study of neuropathic pain, providing a basis for further research on the mechanisms and strategies of nerve damage repair (Wen Xiaojuan, Medical Information. Jan. 2018. Vol. 31. No. 1). The CCI model is used in this embodiment.

[0162] Except for the control group, the remaining SD rats were anesthetized by intraperitoneal injection of 10% chloral hydrate saline solution at a dose of 0.3mL per 100g body weight, and then surgical modeling was performed. Carefully cut the skin of the right hind limb of the rat with surgical scissors, cut the muscle, and ligate the sciatic nerve three times with catgut 4-0, with an interval of 1mm, and then suture the muscle and skin, and apply antibiotics to the wound to prevent animal surgical wound infection. According to literature reports, animals show a significant decrease in pain threshold 7-10 days after surgery, which can last for about one month. The pain threshold of the plantar of the rat was detected in about 10 days of modeling, and the pain threshold of each rat was measured 3 times, and the average value was calculated, and random grouping was performed according to the pain threshold of the rat. Administer medication according to the dosing regimen of Table 8, and select four time points of 2h, 4h, 6h, and 8h after administration to detect the pain threshold of the plantar of the rat.

[0163] On the first day of administration, Fig.21 As shown, at 2h and 4h, the three low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h, the parent peptide AJ003 was not significant compared with the model group, and the three low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group. At 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the two medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0164] On the 4th day of administration, Fig. 22 As shown in the figure, at 2h and 4h, the three low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h and 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the positive drug and the medium and high dose groups of AJ003-36 still had significant analgesic activity compared with the model group.

[0165] On the 7th day of administration, if Fig.23 As shown, at 2h and 4h, the three low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h, the parent peptide AJ003 was not significant compared with the model group, and the three low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group. At 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the two medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0166] On the 10th day of administration, Fig.24 As shown, at 2h and 4h, the three low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h, the parent peptide AJ003 was not significant compared with the model group, and the three low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group. At 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the two medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0167] On the 14th day of administration, if Fig.25 As shown, at 2h and 4h, the three low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group. At 6h, the parent peptide AJ003 was not significant compared with the model group, and the three low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group. At 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the two medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0168] Table 8. Dosing schedule for rat CCI model

[0169]

[0170]

[0171] Example 10: Evaluation of the in vivo analgesic activity of candidate modified peptides at different doses in a mouse diabetic neuropathy model

[0172] Except for the control group, the rest of the C57 male mice (Hangzhou Ziyuan Experimental Animal Technology Co., Ltd.) were continuously induced with high-sugar and high-fat feed for about ten weeks. The model group mice were fasted overnight, and streptozotocin (Saen Chemical Technology (Shanghai) Co., Ltd.) was dissolved in citric acid-sodium citrate buffer, and the model group mice were intraperitoneally injected with streptozotocin 70 mg / kg. About two weeks after the injection of streptozotocin, the mechanical pain threshold of the mice was tested. The detection method was to place the mice in a porous wire mesh to adapt to the environment, and then use a flat-headed needle to vertically stimulate the sole of the right hind limb of the mouse. The pain threshold data was collected and recorded using a biological signal acquisition system. The pain threshold of each mouse was measured 3 times, and the average value was finally calculated. The mice were randomly divided into groups and treated according to the pain threshold.

[0173] On the first day of administration, the drugs were administered according to the dosing regimen in Table 9, and the mechanical pain threshold of the mouse plantar was tested at five time points: 0h, 2h, 4h, 6h, and 8h after administration. Fig.26 As shown, at 2h and 4h, the low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group; at 6h and 8h, there was no significance between the parent peptide AJ003 and the model group, and the low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0174] On the fourth day of administration, the drugs were administered according to the dosing regimen in Table 9, and the mechanical pain threshold of the mouse plantar was tested at five time points: 0h, 2h, 4h, 6h, and 8h after administration. Fig. 27 As shown, at 2h and 4h, the low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group; at 6h and 8h, there was no significance between the parent peptide AJ003 and the model group, and the low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0175] On the 8th day of administration, the drugs were administered according to the dosing regimen in Table 9, and the mechanical pain threshold of the mouse plantar was tested at five time points: 0h, 2h, 4h, 6h, and 8h after administration. Fig.28 As shown, at 2h and 4h, the low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group; at 6h and 8h, the low dose groups of the parent peptide AJ003 and AJ003-36 were not significant compared with the model group, and the medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0176] On the 14th day of administration, the drugs were administered according to the dosing regimen in Table 9, and the mechanical pain threshold of the plantar of mice was tested at five time points: 0h, 2h, 4h, 6h, and 8h after administration. Fig.29 As shown, at 2h and 4h, the low, medium and high dose groups of the positive drug pregabalin, the parent peptide AJ003 and the candidate modified peptide AJ003-36 all had significant analgesic activity compared with the model group; at 6h and 8h, there was no significance between the parent peptide AJ003 and the model group, and the low, medium and high dose groups of the positive drug and AJ003-36 still had significant analgesic activity compared with the model group.

[0177] Based on the mechanical pain threshold test results of the four drug administration treatments, the mother peptide AJ003 has significant analgesic activity in this model within 4 hours compared with the model group, and the analgesic activity is not significant after 4 hours. The medium and high doses of the candidate modified peptide AJ003-36 have significant analgesic activity compared with the model group at 2 to 8 hours of detection; the low dose group of AJ003-36 has no significant difference compared with the model group when tested on the 8th day, but has significant analgesic activity compared with the model group in the other three tests; the analgesic activity of the high dose group of AJ003-36 is slightly better than that of the positive drug pregabalin. This experiment suggests that the candidate modified peptide AJ003-36 can treat diabetic induced neuropathy by subcutaneous injection.

[0178] Table 9. Dosing schedule for the mouse diabetic neuropathy model

[0179]

Claims

1. A peptide, the sequence of which from N-terminus to C-terminus is selected from any one of the following: SEQ ID NOs: 1-5, SEQ ID NOs: 10-16 and SEQ ID NOs: 20-34. 2 . The peptide according to claim 1 , wherein the sequence of the peptide from N-terminus to C-terminus is selected from any one of the following: SEQ ID NOs: 26, 28 and 32.

3. A pharmaceutical composition comprising the peptide according to claim 1 or 2 and a pharmaceutically acceptable carrier or salt.

4. Use of the peptide according to claim 1 or 2 or the pharmaceutical composition according to claim 3 in the preparation of a medicament for treating pain, wherein the pain is selected from neuropathic pain or inflammatory pain.

5. The method according to claim 4, wherein the drug is administered by subcutaneous injection, intramuscular injection, intravenous injection, intraperitoneal injection, intrathecal injection, oral administration, transdermal administration, pulmonary administration, ocular administration or topical administration.

6. The method according to claim 4, wherein the pain comprises pain caused by chemotherapy, diabetic peripheral neuropathy, sciatica, bone and joint pain, postherpetic neuralgia, infection pain, nutritional deficiency pain, inflammatory pain, chronic alcoholism pain, hypothyroidism pain, autoimmune disease pain, Guillain-Barré syndrome pain, poisoning pain, drug-induced pain, tumor lesion pain, genetic disease pain and contusion pain.